Open original FDA record ↗Recall record
- FDA identifier
- Z-1058-2022
- Company in FDA record
- PROTERIXBIO
- FDA record creation date
- May 11, 2022
- First observed by MedTech Watch
- Nov 16, 2026
- Latest observed content change
- Nov 16, 2026
- Recall classification
- Class II
Reason stated in the source
FDA review concluded that the test is insufficiently supported by clinical performance data, and results reported may not have been accurate (false positives or false negatives).
Source facts
- Action
- On April 17, 2022, the firm notified affected physicians who had ordered tests and received results since September 2020 via email. Customers were informed that the prior test results may not have been accurate. In addition, customers were instructed to check their stock and destroy any remaining Dried Blood Spot Collection Kits (ProterixBio SARS-CoV-2 RBD Antibody Test sampling kits). Customers should note the number of kits destroyed in their response to the recalling firm. For questions and clarifications regarding this notification please call ProterixBio at 978-901-6649 or email support@proterixbio.com. Business hours are 8 am to 4:30 pm, Eastern Time.
- Initiated
- 2022-04-17
- Root cause
- Other
- Terminated
- 2024-01-23
- Distribution
- Domestic distribution to CA CO FL IA MA MO NH NY OH OK TX VA
- Recall number
- Z-1058-2022
- Recall status
- Terminated
- CDRH record ID
- 193473
- FDA record created
- 2022-05-11
- Recall event number
- 90107